New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT03202940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two targeted drugs, alectinib and cobimetinib, can safely treat advanced ALK-positive non-small cell lung cancer. Researchers will first find the best dose with acceptable side effects, then measure how often tumors shrink. The trial enrolls 16 adults whose cancer has spread and carries the ALK gene change.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alectinib and cobimetinib
What this could lead to
If this combination works, it could offer a new treatment option for people with ALK-positive lung cancer whose disease has stopped responding to standard therapy.
What could go wrong
This is an early-phase trial with only 16 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States